Visual Abstract
Aim: There has been increased emphasis on psychosocial outcomes and mental health support for people with T1D. We assessed demographic and diabetes factors related to poorer psychosocial outcomes over 1 year in teens with T1D.
Methods: At 0, 6, and 12 mo, teens (ages 13-17) and parents completed validated measures of diabetes distress, diabetes self-efficacy, and general teen quality of life; teens also reported depressive symptoms. Linear mixed models assessed demographic and diabetes factors predicting teen- and parent-reported psychosocial outcomes over 1 yr.
Results: Teens (N=283, 51% male, 78% white) were M±SD age 15.0±1.3 yrs, with T1D duration 6.6±3.8 yrs, BGM frequency 4.3±2.0 times/day, and A1c 8.5±1.1%; 60% used pumps, 84% had 2-parent families, and 69% had a college educated parent. Risk factors for teen- and parent-reported psychosocial outcomes shared little overlap (Table). Teen reports of poorer psychosocial outcomes were mainly associated with demographic factors (sex, parent education) while parent reports were mainly associated with diabetes factors (A1c, T1D duration, BGM, insulin regimen).
Conclusions: For teens with T1D and parents, different factors are associated with adverse psychosocial outcomes. Consideration of both demographic and diabetes-specific factors is important to help providers identify psychosocial risks and provide timely support to families.
P. V. Commissariat: None. L. J. Tinsley: None. L. K. Volkening: None. R. M. Wasserman: None. B. Anderson: None. L. M. Laffel: Consultant; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Dexcom, Inc., Dompe, Insulogic LLC, Janssen Pharmaceuticals, Inc., Laxmi Therapeutic Devices, LifeScan, Lilly Diabetes, Medtronic, Provention Bio, Inc.
National Institutes of Health (R01DK095273, K12DK094721, P30DK036836); JDRF (2-SRA-2014-253-M-B)
